NASDAQ · Biotechnology

Immunocore Holdings plc (IMCR) Stock

$31.95 -3.42% NASDAQ: IMCR Healthcare

Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders.

Valuation

MetricValue
Price$31.95
Market Cap$1.62B
P/E Ratio-85.34
P/B Ratio4.12
P/S Ratio4.21
EPS (TTM)$-0.53
52-Week High$40.72
52-Week Low$27.56
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-4.83%
ROA-1.76%
ROCE-3.53%
Gross Margin98.81%
Operating Margin-7.61%
Net Margin-4.88%
Debt/Equity1.11
Current Ratio4.18

Annual Financials (USD)

Metric20212022202320242025
Revenue$27.0M$144.0M$197.0M$248.0M$298.0M
Operating Profit$-129.0M$-43.0M$-47.0M$-56.0M$-34.0M
Net Profit$-133.0M$-43.0M$-44.0M$-41.0M$-26.0M
EPS$-3.00$-0.95$-0.89$-1.02$-0.53
Op Margin-478.5%-29.7%-23.9%-22.7%-11.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$407.0M$527.0M$472.0M$1.0B$1.1B
Total Liabilities$176.0M$188.0M$181.0M$649.0M$686.0M
Cash$321.0M$402.0M$350.0M$456.0M$468.0M
Borrowings$86.0M$81.0M$66.0M$433.0M$437.0M

Latest News

Is Immunocore Holdings (IMCR) Undervalued After Its Recent Share Price Rebound? Simply Wall St. · Jul 9, 2026 AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study Zacks · Jul 7, 2026 TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia Zacks · Jul 7, 2026 Reasons Why Investors Should Consider Betting on Neurocrine Stock Zacks · Jul 6, 2026 UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal Zacks · Jul 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-143.0M$-49.0M$2.0M$26.0M$-8.0M
Investing Cash Flow$-3.0M$-4.0M$-9.0M$-360.0M$-15.0M
Financing Cash Flow$1.0M$6.0M$27.0M$-15.0M$0
Net Cash Flow$144.0M$81.0M$32.0M$13.0M$9.0M
Free Cash Flow$-144.0M$-51.0M$-2.0M$21.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio9.51
EV / EBITDA257.52
FCF Yield-1.89%
Quick Ratio4.15
Interest Coverage-2.56
Return 1Y-0.97%
Return 3Y-44.64%
Return 5Y3.33%

Ownership

Insiders Held0.07%
Institutions Held104.47%
Institutions Float Held104.54%
Institutional HolderSharesReport Date
RTW Investments LP4,869,7982026-03-31
FMR, LLC4,829,1542026-03-31
Wellington Management Group, LLP4,706,1682026-03-31
Primecap Management Company3,693,2412026-03-31
Bellevue Group AG2,796,8032026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABCL $6.93 +6.13% -5.91 $2.12B 0.00%
BHVN $14.07 +3.19% -6.11 $2.12B 0.00%
CLDX $35.80 +0.63% -7.84 $2.38B 0.00%
HRMY $38.24 -1.39% 11.23 $2.21B 0.00%
JANX $16.04 +0.25% -7.78 $978.19M 0.00%

About Immunocore Holdings plc

Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.

Immunocore Holdings plc is headquartered in GB.

Immunocore Holdings plc (IMCR) stock trades at $31.95 with a market capitalization of $1.62B. The stock is valued at a price-to-earnings (P/E) ratio of -85.34, price-to-book of 4.12, price-to-sales of 4.21. Over the past 52 weeks the stock has ranged between $27.56 and $40.72, and currently trades 21.5% below its 52-week high.

On profitability, Immunocore Holdings plc generates a return on equity (ROE) of -4.83%, return on capital employed of -3.53%, an operating margin of -7.61%, a net profit margin of -4.88%.

Official website: www.immunocore.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides